Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

About this update from Cosmos Health Inc.

CHICAGO, July 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share. The Company has now repurchased a total of 5,112,000 shares for approximately $1.11 million under its previously announced share repurchase program of up to $5 million. Under the program, Cosmos Health may repurchase shares from time to time in the open market, through privately negotiated transactions, or through other permitted means, in accordance with SEC Rules 10b5-1 and 10b-18 and other applicable rules and regulations. The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company’s sole discretion.Greg Siokas, CEO of Cosmos Health, stated: "Reaching over five million shares repurchased underscores our continued commitment to the program and our belief that the Company’s shares remain undervalued relative to the strength and potential of our business.”About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC pro...

View stock analysis, news, and events for Cosmos Health Inc.